American Group Psychotherapy Association’s Post

Launching A Therapy Group can be daunting, but the impact is well worth the effort, both for the practitioner and the group members. Learn how in my upcoming virtual event. https://lnkd.in/gK4F2Zch #CounselingPractice #GroupTherapy #TherapyPractice

A morning lesson from #dia2024: Avoid the shiny object syndrome. DHTs can add tremendous value to clinical trial data capture and measurement of efficacy and safety in patients. They can be kind of shiny, new and maybe even get us super excited about possibilities. I love that! And: Take the time to understand your objectives, the use case, the patient need, and the data that already exists about the DHT. Engage early and often with your partners, and know that the regulators are partners who want to help you. In fact, the regulators are people too (a key message from the podium ❤️). Be courageous. Set a strategy by asking lots of questions, aligning internally and with your DHT partners. Then get specific in asking for advice from regulators. They want to help you make decisions for DHT fit-for-purpose use cases. Don’t be distracted by the shiny object. Be strategic and let the object shine in your strategy.

Do you know how payment models influence practice strategies and organizational priorities? Not happy about the changes you've seen in practice? Want to be a part of the solution? Attend the virtual Amplify Therapy Summit! CEUs, recordings, and networking. Exclusive discounts ending soon! #otadvocate #occupationaltherapy #OTadvocacy #occupationaltherapist #occupationaltherapyassistant #occupationaltherapystudent #OTpractice #otpolicy

Laboratory-initiated, cohort-level reanalysis performed as part of the Ambry Patient for Life Program leads to significantly more meaningful answers for patients. This program is a unique, premium service provided at no additional cost for patients who have exome testing at Ambry. #exome #PatientforLife Download the PFL white paper to read more: https://hubs.ly/Q02rPF2Q0

One thought from #DIA2024 to share (thanks Lani Hashimoto for capturing): things that are standard now, were once deemed unnecessary, controversial, too progressive, or "not how we do things." Just stop with that nonsense. Trial participants deserve the respect and gratitude to know their trial health information and attempts to deny them that information is lazy, selfish, or both - not to mention unethical and in some cases dangerous. Give patients the information they (and their HCPs) need for the entirety of their health journey, and stop giving excuses. Figure it out. If you can't, call me and I'll figure it out for you. Like Eddie Vedder sang, "It's evolution, baby..." #patientdatareturn #returnofresults #individualreturnofresults #laysummaries

Our CEO, Dr. Ofer Sharon, spoke to Medtech Insight about our PROphet® platform, how #proteomics and #multiomics approaches are set to shift the industry and the complicated nature of commercial strategies for companion #diagnostics. “What we do with PROphet is improve the resolution of existing treatment guidelines. Physicians don’t like l differentiating from these, so we offer more personalized #treatment choices demonstrating the potential to improve overall survival, without asking them to do anything off-label.” Read it all here: https://lnkd.in/drhpdpCe #LCSM

Workplace wellness is key to having more productive, happier, and engaged employees to benefit your organization! DM me to find out more about our program!

ZOLL LifeVest - The only WCD with RCT Data and 20+ years of clinical evidence you can trust. Explore how LifeVest innovations continue to transform the WCD experience: bit.ly/3VxKUoM

Different individuals, different treatment effects!📈📉📊 Come and join me today at posters WE702 to find out how people with chronic pain benefit from our co-developed, blended-care ACT-based treatment! The visual analysis of our ongoing SCED study is completed, thanks to Haya Al Sharaa, and most patients benefit from the treatment on various outcomes. However, also some negative effect appear. This study demonstrates why SCED studies are key to unpack what works for whom! #WC2024 #DAHLIApainproject #chronicpain #ACT #digital Rikard Wicksell, Afra Taygar, Suzanne Petersson, Ida Flink, katja boersma, Laura Simons, Lance McCracken, Patrick Onghena, Johan Vlaeyen, Karolinska Institutet

📢 Groundbreaking Update in Diagnostics Assessment! 📢 For the first time, the IQWiG has completed a benefit assessment for a diagnostic in Germany. The evaluation revealed no additional benefit for the diagnostic tool under review. It will be seen which impact such assessments might have on the availability of latest diagnostics in Germany. Other reimbursement routes might still apply. 🔗 Read more about the assessment: https://lnkd.in/evaFTrWx #HealthcareInnovation #Diagnostics #IQWiG #BenefitAssessment #MedicalEvaluation #PatientCare #MArS #MarketAccess Copyright picture: © Ralf Baumgarten